Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2022-09-05 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
方生物科技（上海）股份有限公司募集资金管理制度
Governance Information Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the company's internal policies and procedures for managing raised funds, including storage, usage, supervision, and changes in use. It references compliance with laws and stock exchange rules, and includes detailed governance and operational rules for managing capital raised through securities issuance. There is no indication that this is an announcement or a brief summary; rather, it is a comprehensive internal policy document. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a regulatory filing or announcement but a governance-related document outlining internal rules and procedures. Therefore, the best fit is Governance Information (CGR).
2022-09-05 Chinese
中信证券股份有限公司关于益方生物科技（上海）股份有限公司增加部分募集资金投资项目实施主体的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the addition of implementation entities for certain fundraising investment projects by Yifang Biotechnology (Shanghai) Co., Ltd. It references regulatory approvals, fundraising amounts, adjustments to investment projects, and compliance with relevant securities regulations. The document includes detailed descriptions of the fundraising projects, changes in project implementation entities, and opinions from independent directors and the supervisory board. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a regulatory compliance and verification report related to fundraising project management and use, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories such as Capital/Financing Update (CAP) or Audit Report (AR). The document length is about 4101 characters, which is relatively short but contains substantive content rather than just an announcement or certification letter, so it is not RPA or purely a certification. Therefore, the best classification is Regulatory Filings (RNS).
2022-09-05 Chinese
益方生物科技（上海）股份有限公司独立董事关于公司第一届董事会2022年第六次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding several proposals discussed at the company's first board meeting in 2022. The content focuses on approval and opinions about the use and management of raised funds, compliance with regulatory guidelines, and procedural correctness. It does not contain financial statements or detailed financial data but rather expresses independent directors' opinions on board meeting agenda items related to fundraising and fund usage. This type of document is typically related to board or management information, specifically opinions or announcements about board meeting resolutions and related governance matters. It is not a full annual or interim report, audit report, or earnings release. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and does not indicate it is a report publication announcement or regulatory filing. Confidence is high given the clear nature of the document as independent directors' opinions on board meeting proposals.
2022-09-05 Chinese
益方生物关于召开2022年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting of shareholders for a company, including details about the meeting date, voting methods, agenda items, registration procedures, and an attached proxy authorization form. It does not contain financial statements or results but is an announcement related to a shareholders meeting. The content fits the category of materials shared for a shareholders meeting, specifically an Extraordinary General Meeting (EGM) notice. Since the filing definitions include AGM Information (AGM-R) for presentations and materials shared during the Annual General Meeting, and this is a notice for a shareholders meeting (though an extraordinary one), the closest and most appropriate category is AGM Information (AGM-R). The document length is under 5,000 characters, but it is not merely an announcement of a report publication; it is the actual meeting notice and materials. Therefore, the classification is AGM-R with high confidence.
2022-09-05 Chinese
益方生物第一届监事会2022年第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the second meeting of the first Supervisory Board of Yifang Bio-Technology (Shanghai) Co., Ltd. It details the meeting attendance, the agenda items discussed, and the voting results on various proposals related to the use and management of raised funds. The document references compliance with regulatory guidelines and laws but does not contain financial statements or detailed financial data. It is a corporate governance announcement about supervisory board decisions rather than a full report or financial disclosure. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or management bodies.
2022-09-05 Chinese
益方生物科技（上海）股份有限公司章程（2022年9月修订）
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for 益方生物科技（上海）股份有限公司 (InventisBio Co., Limited). It includes chapters on general provisions, business scope, share issuance, shareholder meetings, board of directors, management, supervisory board, financial accounting system, profit distribution, audit, notices and announcements, mergers, amendments to the charter, and other governance-related topics. The content is focused on the company's internal governance structure, shareholder rights, board responsibilities, and procedural rules. There is no indication of financial statements, audit opinions, earnings data, or regulatory filings related to financial results. The document is not a report of financial performance or an announcement of voting results but rather a governance document outlining the company's rules and organizational structure. Therefore, the most appropriate classification is Governance Information (CGR).
2022-09-05 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.